Recent studies revealed that the secretion of glycoprotein stanniocalcin-1 (STC1) is associated with the development and progression of different types of malignant tumors, an observation that has led to the proposal that it could be used as a tumor marker for prostate cancer [12,13,14]. Here, STC1 is linked to prostate carcinoma.